Debatforum

Hej. Ville høre om der er nogen der har en holdning til den teoretiske kurs på en Aktie fra Arbejdernes landsbank? Eller et link til hvor man kan læse noget om det? På forhånd tak. Mvh Steffan

Regnskabet var vidst ok, men ingen opjustering? Investorerne er ikke helt glade idag..

Spændende positiv udvikling i aktien. Mvh. Entreprenøren

På S&P 500 ses en macd topning og faldende Rsi. Det KUNNE .. ligne et oplæg til nogle sure dage OG ENDDA UGER .. forude efterhånden som macd skal kværne ned gennem systemet. Dayli chart: https://invst.ly/uiy04 Ser vi på weekly chart ser vi at en "nedrivning" på dayli faktisk KAN udvikle sig til noget meget ubehageligt, hvis udviklingen fortsætter. Weekly chart: https://invst.ly/uiy4- Noget andet er at det KUNNE .. ligne lidt korrektion efter "den tredje bølge" (Fibonacci) og dermed KAN udvikle sig ubehageligt da nedturen efter 3.de bølge ofte kan være lidt dybere end ønsket. Er vi her midt i april ved at nærme os "sell in may and stay away" ? .. Den bedste indikator er vel at Tom Hougaard er ved at blive bullish ? Dette er ingen facitliste for den enkelte aktie, men TA indikatorerne antyder at risikoen for nogle ubehagelige uger KAN .. ligge forude. Check din portefølge atter engang. Har du en fornuftig blanding, hvis det er der vi skal hen ? Ser indikatorerne ud til at følge din tankegang ? Check Rsi hver dag for dine aktier ! Det er på tide at skærpe din opmærsomhed mod et potentielt surt marked ! mvh TheNote

Der er meget, jeg ikke fatter; nedenstående en ting, jeg gerne vil have forklaring på! Jeg har købt 500 aktier i "Balstyrisk Aktieforløb" til kurs 100. Kursen stiger til kurs 110, og jeg vælger at sætte 300 aktier til salg i kurs 112. (Bare nu HVIS den skulle hoppe derop!) Jeg er godt klar over, at jeg ikke får solgt mine 300 stk, så længe den handles til en kurs under 112.. Jeg er også klar over, at jeg ikke får handlet til kurs 112, så længe ANDRE har ligget i kø foran mig med salg til kurs 112. Men pludselig bliver det MIN tur til at afhænde aktien. På et tidspunkt ryger de første 92, og jeg knytter næven og siger: "Yes", for nu er vi i gang. MEN - så sker det pudsige: pludselig ser jeg et salg fra Nordnet på 334 stk - OGSÅ i kurs 112. Dernæst en handel fra et tredje forum - til kurs 112; og så fra et fjerde forum - til kurs 112; hvorefter jeg får solgt en sjat - inden kursen falder, og jeg ikke får solgt resten af portionen. Nu sidder jeg og bider i bordkanten i raseri - for HVORDAN kunne de tre andre bryde ind i køen, som jo var nået til MIN handelspost? Hvorfor blev mine aktier ikke solgt først, da jeg jo havde ventet på "min tur"? Der blev måske handlet 700 aktier "inde midt i min salgsportion på 300 stk". Er der en rar sjæl med pædagogiske evner, der kan berige mig med sit vid?

Ser ud til vi snart får købssignal på weekly kort. Det har været undervejs den sidste månedstid og historisk set kan man forvente en længere opgangs periode når MACD brydes opad. RIS er også nu over 50 på kortet. Har selv aktier i Genmab. Både korte og lange positioner. [image: 93152_5_aars.png]

I sidste uge kom Biden med sin plan omkring forhøjede skatter på de såkaldte "Capital gains" for de rigeste i USA. Dette medførte en del nervøsitet hos mange investorer. Men spørgsmålet er, hvor meget dette rent faktisk historisk set har betydet for aktiemarkederne. Så jeg har fundet lidt historisk information frem, som vi kan bruge til at navigere efter i nutiden. https://www.youtube.com/watch?v=3h84ETcPH1g

Der kommer regnskab fra cBrain i morgen, en fantastisk aktie. Er der nogen herinde der har an anelyse eller mening på den ?

Hansa Biopharma kan nu for alvor kalde sig kommercielle. Første patient er nu behandlet og vi kan så småt begynde at regne på fremtidig indtægt som vi havde stor fornøjelse af i Veloxis, Genmab mfl. Første reimbursement i Q2/q3 men adgang for patienter inden hvis lokal funding kan skabes som vi har set det i q1. Det er en stor dag for menneskeheden, at patienter hvor det tidligere nærmest har været umuligt at blive behandlet nu kan få hjælp af Hansa Biopharma med IDEFIRIX.. Det siger lidt om potentialet at man blot ved godkendelse i første indikation/område (nyre i EU), potentialt kan få omsætning i mia klassen når der er yderligere 32 indikationer/områder godt på vej foruden at tale om alle de brikker i puslespillet som bliver lagt henadvejen (senest de 2 brikker: 2 indikationer i genterapi, Limb-Girdle og Duchenne) https://s24.q4cdn.com/980434894/files/doc_financials/2021/q1/20210421-Q1-2021-Road-Show-Presentation-FINAL.pdf

I 2017 blev det estimeret at driften af mining i bitcoin kostede 1.5 milliader USD. Det tal er nok ikke blevet mindere siden. Samt investering i mega fabrikkers hardware. Hvem betaler det ? Jeg tror desværre det er de tosser der indbetaler penge for at kommme med i diverse mining pools. Tror ikke elselskaberne og hardware fabrikanter modtager bitcoins som betaling. Nogen skal jo betale . ER DET DIG !!!. Men goog luck med bitcoins investeringen !!!

An impressive quarter, but more to come Despite the extensive shortage in the semiconductor market, Asetek has executed well to exploit the explosive demand from global gaming market. We think customer demand will remain highand the company is on track to deliver the high end of its 2021 guidance. Our EBIT estimates are increased by 2-3% for 2021-23 and our midpoint DCF value is unchanged at NOK 160 per share. Stronger than our upbeat expectation Based on the better-than-expected Q1 results, we have increased our 2021-23 sales estimates by 3%. It is positive that the strong sales of G&E products in Q1 werenot only driven by additional demand caused by extended country lockdowns, but also driven by new product launches and market share gains. The company has delivered four types of new G&E product to its customers in Q1 and plansto deliver another six types of new product in Q2. We think the company has higher-than-normal visibility for its order book and revenue in 2021. We now expect 30% organic growth for 2021, at the high end of its guidance range of 20-30%. Datacenter remains lumpy, but long-term growth outlook is unchanged The main disappointment in Q1 was that thesoft order bookof USD 0.9min Datacenter business, much less than USD 3m in Q4 2020 (USD 0.5m in Q1 2020). However, we acknowledge the lumpiness in this business. Despite the short-term weakness in the order book, our sales estimates remain unchanged for Datacenter. Mid-point DCF valuation remains unchanged at NOK 160 As we fine-tune our assumptions for gross margin and opex, our EBIT estimates increase by 3% for 2021 and 2% for 2020 and beyond. Our mid-point DCF value remains unchanged at NOK 160 per share, which is67% above the current share price. Læs hele analysen på link: 93108_SEB___Asetek_analyse_.pdf

Intel næsten uændret omsætning i Q1 YoY. EPS 37% ned. Men de forudser en EPS på 4 USD i 2021. Ved kurs 60 giver det en PE på 15.

Frie midler/frit depot. Hvis man køber en etf nu og den enten er faldet eller steget ved kommende nytår - kan SKAT automatisk håndtere fradrag eller beskatning? Eller skal man selv registrere noget manuelt? Jeg ved enkeltaktier købt fra 2010 kører automatisk i forhold til SKAT. Beskatningen er enten aktieindkomst eller kapitalindkomst afhængigt af ETF'en. Hvis det er kapitalindkomst og tab er der så ikke direkte fradrag i kapitalindkomst? (Negativ kapitalindkomst). Det er ikke fremførsel af tab til senere modregning i gevinst vel?

Rek: Köp (Köp) Riktkurs: 1 455,00 DKK Pris: 1 205,00 DKK Analytiker: Douglas Lindahl Aktieanalytiker Analysen producerad av Kepler Cheuvreux 2021-04-22 kl. 06:16, och översatt samt distribuerad via Aktiellt 2021-04-22 kl. 09:22 Inför Q1: Vi räknar med en långsam start på året Vestas kommer att släppa sitt resultat för Q1 den 5 maj och vi uppdaterar vår modell inför rapporten. För Q1 förväntar vi oss att orderingång för anläggningar på land har dämpats med tanke på den långsamma inledningen för landbaserad vind globalt. Totalt sett gör vi mindre prognosändringar för de kommande fem åren, eftersom vi justerar ned vinsten per aktie med i genomsnitt 1,1 procent. Vi upprepar Köp med riktkurs 1 455 DKK. Viktiga resultat Vi utgår från att den justerade rörelsemarginalen kommer att uppgå till 4,7 procent under första kvartalet (den var -2,4 procent under första kvartalet 2020), eftersom lönsamheten i orderstocken är högre än för ett år sedan. Sett till resultat- och orderingång så är Q1 det överlägset minst viktiga kvartalet för Vestas. Vi justerar våra prognoser inför första kvartalet 2021, eftersom stigande stålpriser potentiellt kan pressa marginalerna för den landbaserade vindkraften under den senare delen av 2021. Vestas borde kunna kompensera detta eftersom stålet för produktionen säkras när kundkontrakten tecknas, men vi har blivit mer försiktiga kring detta. Vi kommer att lägga extra fokus på vad det genomsnittliga försäljningspriset i orderingången hamnat på, i rapporten, för att se om det har ökat något för att kompensera för stigande insatskostnader. Vestas är fortfarande vårt toppval inom den strukturellt växande vindkraftsindustrin. Prognosöversyn Vi upprepar vårt Köpråd och vår riktkurs på 1 455 DKK. Vi antar att orderingången fortsatt återhämtar sig och högre marginaler under den senare delen av 2021 för Power Solutions. Utsikterna på medellång till lång sikt är fortsatt starka och vi ser cirka 20 procent uppsida.

SP500 giver ca 7% i gns årligt afkast. Tror I SP500 index med rimelig sandsynlighed kan outperformes, hvis man vælger en større vægt af IT aktier eller andre sektorer, der kan tænkes at give et bedre afkast? Det bliver naturligvis gisninger. Skulle det i givet fald sammensættes af flere etf'er eller mange enkeltaktier eller en blanding af etf og emkeltaktier? Hvad ville I gøre og hvorfor?

Webinar om Digizuites virksomhedsstrategi og ambitioner. https://www.youtube.com/watch?v=A31jvYKNtII

The exercise price for the warrants of series TO1 in 2cureX AB has been determined to SEK 13.22 and the subscription period starts April 26, 2021 April 23, 2021 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. 2cureX AB ("2cureX" or the "Company") completed a directed issue of units during the third quarter of 2020. One (1) unit consisted of two (2) newly issued shares and one (1) warrant of series TO1. Each warrant gives the owner the right to subscribe for one (1) new share in the Company. The exercise price for the warrants of series TO1 is to be determined to 70 percent of the volume-weighted average price in the Company's share on Nasdaq First North Growth Market during the measurement period, from April 9, 2021, to April 22, 2021, however not lower than the quota value of the Company's share and not higher than SEK 28.88. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 18.89, therefore, the exercise price for the warrants of series TO1 is set to SEK 13.22. The subscription period for warrants of series TO1 runs from April 26, 2021 up to and including May 7, 2021. If all the warrants of series TO1 are exercised, the Company will receive approximately SEK 32.46 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than May 7, 2021 or sell the warrants no later than May 5, 2021. Please observe that certain nominees might close their application earlier than May 7, 2021. An independent document with complete terms and conditions for the warrants and documents pursuant to chapter 14 section 32 of the Swedish Companies Act will be available at the Company's website, www.2curex.com. Summarized terms for the warrants of series TO1: Subscription period: April 26 - May 7, 2021. Issue size: 2,455,000 warrants of series TO1, which entitles to subscription of 2,455,000 shares. If all the warrants are exercised, The Company will receive approximately SEK 32.46 million before issuing costs. Exercise price: SEK 13.22 per share. Last day for trading warrants of series TO1: May 5, 2021. Dilution etc.: If all warrants are exercised the share capital will increase with SEK 245,500, from SEK 1,484,600, to SEK 1,730,100. If all warrants are exercised the number of shares will increase with 2,455,000 shares, from 14,846,000 shares, to 17,301,000 shares. The dilution at exercise of all warrants amounts to 14.19 percent of the number of shares and 14.19 percent of the number of votes. Note that the warrants that are not exercised at the latest May 7, 2021, or sold at the latest May 5, 2021, will expire without value. For the warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants. How warrants are exercised: Nominee-registered warrants (Custody account) Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information. Direct-registered warrants (Securities account) No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office. The application form including instructions for payment will be available at 2cureX's website, www.2curex.com and on Mangold Fondkommission AB's website, www.mangold.se. Advisers Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal advisor to 2cureX regarding the warrants. For questions regarding the warrants, please contact: Mangold Fondkommission AB Tel: +46 8 5030 1595 E-mail: [email protected] For more information regarding 2cureX, please contact: Fernando Andreu Chief Executive Officer Tel: +45 22 79 53 99 E-mail: [email protected] Certified Adviser Redeye AB Phone: +46 8 121 576 90 Mail: [email protected]

Analyse fra Investment Panel. april 2021 Brødrene A&O Johansen A/S (AO) er en dansk virksomhed, som leverer produkter til både professionelle håndværkere, samt det private marked. Koncernen har over 22.000 B2B-kunder samt 230.000 B2C-kunder, som tilsvarer en vækst på hhv. 10% og 15% siden 2016. Selskabet har et bredt teknisk varesortiment på over 400.000 varevarianter, som servicerer aktiviteter indenfor; Varme, Ventilation og Sanitetsteknik (VVS) El-teknik (EL) Vand og Afløb (VA) Værktøj Koncernen opererer i Danmark, Sverige, Norge og Estland, hvori 90% af aktiviteterne er på det danske marked. De professionelle kunder serviceres af butikkerne af AO-brandet, hvor aktiviteterne for det private marked dækkes af forskellige hjemmesider, heriblandt BilligVVS og LampeGuru. Digital strategi Selskabet er baseret på en digital værdikæde som fundament bag en lang væksthistorie. Virksomheden defineres som et omni-channel selskab, hvilket betyder at virksomheden yder en personaliseret kundeoplevelse gennem flere kanaler. AO beskriver konceptet med: "En kunderejse beskæftiger sig med hele processen; fra et behov opstår, og til rejsen ender - som et køb eller som færdigt projekt.". Selskabet har flere gange modtaget priser for deres strategi. Senest blev de kåret af Dansk Erhverv som værende den bedste omni-channel-virksomhed for 2019, som de tidligere også vandt i 2016. Det seneste koncept, som AO har implementeret, er deres AO365-koncept. Dette koncept tillader de professionelle kunderne adgang til AOs butikker døgnet rundt, alle dage om året. Kunderne kan bestille varer gennem AOs mobil-app, hvor de derefter modtager en digital nøgle til butikken. Derefter åbnes butikken, man handler de ting man skal bruge, og butikken lukkes igen, når man forlader butikken. Dette giverne de professionelle kunder en højere fleksibilitet, samt eliminere deres behov for et lokalt lager. Effekt af nedlukning Nedlukning af Danmark i foråret 2020 medførte en positiv effekt på Brdr. A&O, hvilket deres regnskab for 2020 viste. Her har der været en omsætningsvækst på knap 15%, hvilket bygger på, at kunderne har efterspurgt fleksibilitet ved valg af salgsplatforme og handelsform. Markedet for private renoveringer er generelt stabilt, men gennem COVID-19 har denne skiftet kurs, og styret mod nye højder. Deres omsætning fra professionelle kunder steg med 12%, hvorimod væksten i det private marked var 34% i 2020. Værdiansættelse og konklusion: https://www.financelab.dk/2021/04/18/brodrende-ao-fortsaetter-med-at-bygge-pa/

8.00 AM CEST / 22-Apr-2021 / Hansa Biopharma AB (STO:HNSA) Hansa Biopharma interim report Jan-Mar 2021 First commercial sales of Idefirix recorded in Q1; New preclinical collaboration with argenx; Encouraging three-year follow-up data in kidney transplantation Lund, Sweden April 22, 2021 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January - March, 2021. Highlights for the first quarter 2021 First commercial sales of Idefirix recorded in Q1 2021 following treatment of the first patients. Commercial launch activities in early launch countries continue to be carried out as planned. National level reimbursement application processes underway and decisions by authorities in the first markets expected from mid-year and onwards. First Healthcare Technology Assessment report published in Sweden. The Swedish "TLV" assessment is favorable to the use of Idefirix in highly sensitized patients incompatible with a deceased donor. Hansa Biopharma enters into preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies for potential use in both the acute and chronic setting of autoimmune diseases and transplantation. Encouraging three-year follow-up outcome and safety data in imlifidase treated transplant patents in line with expectations compared to outcomes in patients undergoing HLA-incompatible transplantation. Data expected to be presented later in the year in a peer-reviewed journal. Magnus Korsgren, M.D., Ph.D. appointed new Head of R&D. Dr Korsgren will lead research and development activities based on Hansa's proprietary enzyme technology platform as the Company expands into new therapeutic areas. Patient recruitment in the phase 2 studies in AMR and GBS ongoing under a risk-based, site-by-site approach due to the COVID-19 pandemic. In the AMR trial, 9 out of a target of 30 patients have been enrolled, and in the GBS trial 8 out of 30 have been enrolled. US trial: Hansa continues to be in productive dialogue with the FDA and expects to reach an agreement near-term with the Agency on the protocol for a randomized controlled study in the US. Preparatory work to initiate the trial is ongoing. Hansa expects to initiate the trial over summer and to recruit the first patient in the second half of 2021. COVID-19 pandemic: The global COVID-19 pandemic may still adversely impact Hansa Biopharma's operational business and trial activities. Events after the end of the reporting period Hilary Malone, PhD. in Molecular Neuropharmacology (born 1965, U.S. and UK citizen) proposed as new member of the Board of Directors at the next AGM. Dr. Malone is currently COO and EVP at Valo Health, Inc. (U.S.) and has held global executive positions at Sanofi, Reata Pharmaceuticals, Pfizer, Wyeth and AstraZeneca, among others. Birgit Stattin Norinder has decided not to stand for re-election to the Board of Directors at the next AGM. Financial summary Solid cash position of SEK 1,255m at the end of March 2021. Investments in SG&A and R&D in the first quarter amounting to SEK 60m (Q1'20: SEK 39m) and SEK 47m (Q1'20: SEK 53m), respectively, in line with plans. Cash flow from operating activities for the first quarter ended at SEK -121m (Q1'20: SEK -121m). SEKm, unless otherwise stated - unaudited Q1 2021 Q1 2020 FY 2020 Revenue 9.0 0.9 6.1 Gross profit 7.3 0.5 5.1 SG&A expenses -60.1 -38.7 -203.0 R&D expenses -47.4 -52.5 -227.2 Operating profit/loss -103.7 -91.4 -422.8 Net profit/loss -103.9 -93.4 -420.9 Cash flow from operating activities -120.9 -121.2 -290.3 Cash and short-term investments 1,254.7 476.9 1,377.5 Shareholders' equity 1,149.8 473.9 1,242.1 EPS before and after dilution (SEK) -2.34 -2.33 -9.98 Number of outstanding shares 44,473,452 40,026,107 44,473,452 Weighted avg. number of shares before and after dilution 44,473,452 40,026,107 42,176,872 Number of employees 101 78 87 Søren Tulstrup, President and CEO of Hansa Biopharma, comments: "Hansa Biopharma's evolution into a fully integrated, commercial-stage biopharmaceutical company is now a reality following the Company's first commercial sales of Idefirix and treatments of the first patients. Our long-term objective is to build Hansa into a recognized global leader in rare diseases across multiple broad therapeutic areas through the development of new transformative medicines for patients suffering from rare immunologic diseases. In order to do so, we need to successfully execute on our strategic priorities. This early in 2021, we have already demonstrated clear progress across our business and organization and that we are on track to deliver on our targets for the year. In Europe, our commercial launch activities continue to be rolled out and implemented in early launch countries as planned. As part of this effort, we continue to have close interactions with national reimbursement authorities and leading transplant clinics. Decisions by authorities in the first of the early launch countries can be expected from mid-year and onwards following publication of Healthcare Technology Assessments to evaluate the health-economic impact from using Idefirix. A first such assessment was recently published in Sweden, which was favorable to the use of Idefirix in scenarios representing both high and low mortality assumptions for dialysis patients. On March 29, Hansa entered into a preclinical research collaboration agreement with argenx BV to explore the potential of combining imlifidase, Hansa's IgG antibody-cleaving enzyme, and efgartigimod, argenx's FcRn antagonist. We are pleased to collaborate with argenx, a leader in the field of FcRn-inhibition, as they share our commitment to bringing innovative new medicines to patients suffering from autoimmune diseases. A combination of imlifidase and efgartigimod could potentially be used in both the acute and chronic setting of autoimmune diseases and transplantation and may potentially unlock additional therapeutic value. In the US, Hansa is in productive dialogue with the FDA and we expect to finalize near-term an agreement with the Agency on a protocol for a randomized controlled study in the US. Preparatory work to initiate the trial is already ongoing and we are encouraged by the strong interest shown by leading US transplant centers to participate in the trial. Subject to the expected agreement with FDA on the study protocol in the coming months, we expect study initiation over the summer and the first patient to be enrolled in the second half of 2021. In our ongoing phase 2 programs, GBS and AMR, we see patient enrollment progressing again following a temporary halt in the recruitment process during large parts of 2020 due to the COVID-19 pandemic. In December 2020, patient enrollment was reinitiated in both studies under a risk-based, site-by-site approach. As of April 21, 2021, 9 out of a target of 30 patients have now been enrolled in the AMR study, while 8 out of 30 have been enrolled in the GBS study. Depending on the impact of the COVID-19 pandemic, enrollment is expected to be completed towards the end of 2021, as previously guided. Furthermore, I am pleased to announce that our long-term follow-up study in highly sensitized kidney patients continues to show encouraging outcomes after imlifidase treatment and transplantation. We now have three-year data available, demonstrating follow-up outcomes in line with expectations compared to outcomes in patients undergoing HLA-incompatible transplantation. Data is expected to be published later this year following submission of a manuscript to a peer-reviewed journal. I am also happy to see that we continue to attract the talent and competences needed to build a high-performance organization. In March, we announced the recruitment of Magnus Korsgren, M.D., Ph.D as our new Head of R&D. Dr. Korsgren's extensive international experience in translational medicine and drug development will be very helpful for our continued efforts to build a highly valuable pipeline of drug candidates within transplantation, autoimmune diseases and beyond. Speaking about attracting highly qualified, international competences, I am also very pleased to see Hilary Malone, Ph.D in Molecular Neuropharmacology, being proposed at the next AGM as a new member of the Board of Directors at Hansa Biopharma. Ms. Malone currently holds the position of Executive Vice President and Chief Operating Officer at Valo Health, Inc. in the US and has previously held global executive positions at Sanofi, Reata Pharmaceuticals, Pfizer, Wyeth and AstraZeneca, among others. Hansa is off to a good start in 2021 and I look forward to updating you on our progress as we deliver on our mission to bring lifesaving and life altering therapies to patients with rare diseases who need them while generating value to shareholders and society at large." Upcoming milestones and news flow H1 2021 NiceR: initiate IND-enabling tox studies Q2/Q3 2021 First national reimbursement agreement H2 2021 Kidney transplantation US: First patient dosed H2 2021 AMR Phase 2 study: Complete enrollment H2 2021 GBS Phase 2 study: Complete enrollment H2 2022 Kidney transplantation US: Complete enrollment H2 2022 AMR Phase 2 study: Data read out H2 2022 GBS Phase 2 study: Data read out H2 2023 Kidney transplantation US: 12 months follow-up completed H1 2024 Kidney transplantation US: BLA submission Conference call details Hansa Biopharma will host a telephone conference today Thursday April 22 14:00 CET / 8:00am EST. The presentation will be held in English and be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota. Slides used in the presentation will be live on the company website during the call under "Events & Presentation" and will also be made available online after the call. To participate in the telephone conference, please use the dial-in details provided below: Sweden: +46 8 50 55 83 75 United Kingdom: +44 333 300 90 35 United States: +1 833 526 83 82 The webcast will be available on https://streams.eventcdn.net/hansa/2021q1/ The interim report and latest investor presentation can be downloaded from our web Interim report January - March 2021 https://investors.hansabiopharma.com/English/financial-data/quarterly-report/default.aspx Investor road show presentation Q1, 2021 https://investors.hansabiopharma.com/English/events-and-presentations/presentations/default.aspx This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 E-mail: [email protected] Katja Margell Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: [email protected]

"Jobmarkedet i byggeriet er brandvarmt, og beskæftigelsestallene stiger til nye højder under coronapandemiens fremtog. I 1. kvartal er antallet af beskæftigede i byggebranchen steget med godt 5.500 fra kvartalet før til 187.087. Dermed er tallene ikke kun er højere end før coronakrisen. De er på højeste niveau i 13 år, viser tal fra Danmarks Statistik..." https://www.licitationen.dk/article/view/787867/byggeriet_buldrer_frem_beskaeftigelsen_er_den_hojeste_i_13_ar https://www.dst.dk/da/Statistik/nyt/NytHtml?cid=32012 Jeg tror at A&O Johansen har vokset med minimum 15 % under Q1. Om en uge har vi svaret. Baserat på antal nye elinstallatører borde Solar A/S også kunne vise paen vaekst. I resten av Norden, Europa of Nordamerika vurderes VVS- og elgrossister mellom PE 14 og 24. Hvorfor er det anderledes i Danmark? A&O Johansen er jo desuden "best in show" og borde kunne vurderes til PE=15 som et minimum og då skal aktiekursen op 40-50 %. Idag vurderes hele A&O (stam- og praeferenceaktier) kun 65 % over 2007-2008 (store aktietilbagekøb).